Open AccessGGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates
Author(s) -
Neus RocaAyats,
Susana Balcells,
Natàlia GarciaGiralt,
Maite Falcó-Mascaró,
Núria MartínezGil,
Josep F. Abril,
Roser Urreizti,
Joaquı́n Dopazo,
José Manuel QuesadaGómez,
Xavier Nogués,
Leonardo Mellibovsky,
Daniel PrietoAlhambra,
James E. Dunford,
M K Javaid,
R.G.G. Russell,
Daniel Grinberg,
Adolfo DíezPérez
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmc1612804
Subject(s) - medicine , mutation , bone density conservation agents , surgery , genetics , osteoporosis , bone density , gene , biology
Atypical femoral fractures have been associated with long-term bisphosphonate treatment.1,2 However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral fractures after receiving various oral bisphosphonates for 6 years. Two of the sisters had a single fracture (at the ages of 64 and 73 years), and one had bilateral fractures (one at the age of 60 years and the other at the age of 61 years). Given the low incidence of atypical femoral fractures in the general population (5.9 per 10,000 person-years),3 we hypothesized that these sisters might have an underlying genetic background that contributed to these fractures
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom